Highlights Chronic Airway Therapeutics (CAT) selects R&G Pharma to progress Chinese development of nadolol R&G is one of China’s leading Contract Research Organisations CAT, R&G ready to commence regulatory process and will request pre-IND meeting with China Food and Drug Administration Melbourne, Australia and Delaware, United States, 27 September 2018: Chronic Airway Therapeutics (CAT), a…
Read more
New formulation of Photosoft therapy shows increased effect in ovarian cancer
New in vitro data shows effectiveness of IVX-P02, an improved formulation of Photosoft™ Oral IVX-P02 is 15 times more effective than Photosoft™ Oral at killing ovarian cancer cells in vivo animal trials to be commenced this year, moving to human clinical trials in 2019 Melbourne, Australia, 25 September 2018: Cancer therapy developer Invion Limited (ASX:…
Read more
Invion to spinout respiratory assets and advance clinical development in China
Invion to demerge respiratory assets into stand-alone company, Chronic Airway Therapeutics Limited (CAT) CAT to focus on development of respiratory assets in China, expediting advancement into Phase 3 clinical trials Eligible Invion shareholders will, on completion of the demerger, receive one share in Chronic Airway Therapeutics Limited for each Invion share they hold Melbourne, Australia…
Read more
Photosoft efficiently destroys ovarian cancer cells in vitro
Invion and Hudson Institute of Medical Research are collaborating on R&D projects for the PhotosoftTM technology as a treatment of a range of cancers PhotosoftTM characterisation studies have been completed in multiple ovarian cancer cell lines PhotosoftTM caused efficient and highly effective cancer cell destruction in vitro Melbourne, Australia, 5 July 2018: Invion Limited (ASX:…
Read more